Skip to main content
Premium Trial:

Request an Annual Quote

New York, Florida, and California License Genomas Laboratory

NEW YORK (GenomeWeb News) – Pharmacogenomics firm Genomas today announced it has obtained clinical laboratory licenses from New York, Florida, and California.

The company's Laboratory of Personalized Health received CLIA certification in 2005, the same year the lab received licensure from Connecticut.

Last year, Genomas was credentialed as a Medicare provider and began providing services in Texas and Pennsylvania.

"New York, Florida, and California are among the most demanding states in terms of laboratory technical expertise and business credentialing," Gualberto Ruano, president of Genomas and director of the Laboratory of Personalized Health, said in a statement. "Now we are determined to bring our clinical pharmacogenetics services to the people of these states and the entire nation."

In 2005 Genomas launched it HILOmet PhyzioType system and inked a distribution agreement with Clinical Laboratory Partners. Today Genomas, based in Hartford, Conn., said that more than 500 clinicians and 5,000 patients had benefitted from the test, which enables personalized management of more than 250 drugs targeted at mental illness, pain, diabetes, and heart disease.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.